Can you expect healthy growth in pharma stocks now? Here's what top brokerages recommend
Jefferies and HSBC have recommended, Cipla, Sun Pharma, Divi's Laboratories, Biocon, Lupin and others
Pharma stocks have been among the worst hit spaces on Dalal Street in the past few months. The Nifty Pharma -- whose 20 constituents include some of the country's largest drug makers such as Sun Pharma, Cipla, Dr Reddy's and Divi's -- has lost more than nine per cent of its value in the past one year, a period in which the Nifty50 benchmark has declined almost two per cent.
Brokerages have mixed views on pharma stocks at the current juncture.
According to Anand Rathi, there was a pickup in demand in the acute therapy segment in the pharma sector in December 2022. Despite high bases, price hikes should aid decent growth for companies operating in acute therapies and volume growth momentum should continue in the chronic therapy segment, the brokerage said in a research report.
Also Read: Budget 2023: Experts eye big push for infrastructure sector from government
Anand Rathi is positive on chronic therapy-focused companies such as Abbott, Ajanta Cipla, JB Chemicals, Eris and Torrent Pharma.
Cipla
Jefferies downgraded Cipla to 'hold' from 'buy' and reduced its target by Rs 219 to Rs 1,100 apiece -- implying two per cent upside potential from Tuesday's closing price.
HSBC maintained a 'buy' on the stock and raised its target price by Rs 10 to Rs 1,350.
Sun Pharma
Jefferies maintained a 'buy' call on Sun Pharmaceutical Industries and raised its target prce by Rs 16 to Rs 1,200 apiece.
HSBC also retained a 'buy' on the stock. The brokerage raised its target by Rs 20 to Rs 1,210 apiece.
Sun Pharma said on Wednesday that one of its wholly-owned subsidiaries has launched a novel anti-cancer drug, Palbociclib, in India for patients who have advanced breast cancer.
Divi’s Laboraties
Jefferies continued with an 'underperform' on Divi’s Labs but raised its target to Rs 3,045 from Rs 3,017.
HSBC maintained a 'hold' on the stock and raised its target to Rs 3,440 from Rs 3,425.
Also Read: Budget 2023: Why agri stocks are in focus prior to Budget
Biocon
Jefferies downgraded Biocon to 'hold' from 'buy' and reduced its target to Rs 285 from Rs 357. Yet, the brokerage's target price implies upside potential of 10.5 per cent from its closing price on Tuesday.
HSBC maintained 'hold' on Biocon and brought down its target to Rs 300 from Rs 325.
Lupin
Jefferies retained an 'underperform' rating on Lupin and raised its target price for the stock by Re 1 to Rs 650.
HSBC, on the other hand, upgraded Lupin to 'buy' from 'hold' and raised its target for the stock to Rs 860 from Rs 715.
Laurus Labs
Jefferies downgraded Laurus to 'hold' from 'buy' and reduced its target to Rs 395 from Rs 567.
Alkem Labs
Jefferies maintained 'underperform' on Alkem and lowered its target for the stock to Rs 2,600 from Rs 2,802.
HSBC continued with its 'buy' rating on Alkem but reduced its target to Rs 3,555 from Rs 3,735.
Torrent Pharma
Jefferies maintained 'hold' on Torrent Pharma and raised its target for the stock to Rs 1,620 from Rs 1,505.
Click here to get more updates on Stock Market I Zee Business Live
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SBI Amrit Vrishti FD vs Central Bank of India 444-day FD: Which gives higher return to senior citizens on Rs 10 lakh and Rs 20 lakh investments
SIP Calculator: How soon can you build Rs 2 crore retirement corpus by investing Rs 5,100, Rs 11,000 or Rs 21,000 a month; see examples
SBI Sarvottam FD vs Union Bank Sumvridhi FD For Senior Citizens: What will be returns on Rs 5 lakh investment in each guaranteed return scheme
02:14 PM IST